Home | Log In | Register | Our Services | My Account | Contact | Help |
Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsThe evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Thursday 31st March 2016
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:18.00 | Registration and coffee | |
18.30 | Presentations • James Parsons, CEO - Sound Energy (SOU) • Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR) • Dr. George Morris, Chief Operations Officer - Valirx (VAL) + More to be announced | |
20.30 | Drinks reception and canapés | |
21.30 | Close |
![]() | Sound Energy is a well-funded Mediterranean upstream company, listed on AIM, with cost covering production, a cornerstone investor, a strategic partnership with Schlumberger (one of the largest companies in our sector) and an active and potentially transformational drill programme. |
![]() | Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs. |
![]() | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |